Joshua Tobias

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 14

Top Venues

Pharmaceutics

Vaccines

International journal of molecular sciences

Cancers

Medical University of Vienna

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Medical University of Vienna

Austria

Scientist :: Institute of Specific Prophylaxis and Tropical Medicine

Publications

Joshua Tobias, Peter Steinberger, Joy Wilkinson, Gloria Klais, Michael Kundi, Ursula Wiedermann
SARS-CoV-2 Vaccines: The Advantage of Mucosal Vaccine Delivery and Local Immunity. Vaccines 12 (7) (2024)
Joshua Tobias, Marina Maglakelidze, Zoran Andrić, Dinara Ryspayeva, Iurie Bulat, Ivan Nikolić, Zoran Petrovic, Tanuj Chawla, Rajnish Nagarkar, Erika Garner-Spitzer, Christoph C Zielinski, Leslie Mi Ok Chong, Bonnie Nixon, Nicholas J Ede, Sharon Yavrom, Michael Kundi, Ursula Wiedermann
Phase II trial of HER-Vaxx, a B cell peptide-based vaccine, in HER2-overexpressing advanced gastric cancer patients under platinum-based chemotherapy (HERIZON). Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Joshua Tobias, Peter Steinberger, Joy Wilkinson, Gloria Klais, Michael Kundi, Ursula Wiedermann
SARS-CoV-2 Vaccines: The Advantage of Mucosal Vaccine Delivery and Local Immunity. Vaccines 12 (7) (2024)
Joshua Tobias, Peter Steinberger, Joy Wilkinson, Gloria Klais, Michael Kundi, Ursula Wiedermann
SARS-CoV-2 Vaccines: The Advantage of Mucosal Vaccine Delivery and Local Immunity. Vaccines 12 (7) (2024)
Joshua Tobias, Sandra Högler, Martin Raigel, Diego Shih-Chieh Lin, Yee Chao, Lukas Kenner, Erika Garner-Spitzer, Sharon Yavrom, Nicholas J Ede, Christoph C Zielinski, Michael Kundi, Ursula Wiedermann
Preclinical and Clinical Observations Implying Combination Therapy to Enhance the Efficacy of the Her-2/neu B-Cell Peptide-Based Vaccine HER-Vaxx and to Prevent Immune Evasion. International journal of molecular sciences 25 (1) (2023)
Joshua Tobias, Sandra Högler, Martin Raigel, Diego Shih-Chieh Lin, Yee Chao, Lukas Kenner, Erika Garner-Spitzer, Sharon Yavrom, Nicholas J Ede, Christoph C Zielinski, Michael Kundi, Ursula Wiedermann
Preclinical and Clinical Observations Implying Combination Therapy to Enhance the Efficacy of the Her-2/neu B-Cell Peptide-Based Vaccine HER-Vaxx and to Prevent Immune Evasion. International journal of molecular sciences 25 (1) (2023)
Joshua Tobias, Sandra Högler, Martin Raigel, Diego Shih-Chieh Lin, Yee Chao, Lukas Kenner, Erika Garner-Spitzer, Sharon Yavrom, Nicholas J Ede, Christoph C Zielinski, Michael Kundi, Ursula Wiedermann
Preclinical and Clinical Observations Implying Combination Therapy to Enhance the Efficacy of the Her-2/neu B-Cell Peptide-Based Vaccine HER-Vaxx and to Prevent Immune Evasion. International journal of molecular sciences 25 (1) (2023)
Joshua Tobias, Mirjana Drinić, Anna Schmid, Anastasiya Hladik, Martin L Watzenböck, Claire Battin, Erika Garner-Spitzer, Peter Steinberger, Michael Kundi, Sylvia Knapp, Christoph C Zielinski, Ursula Wiedermann
Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer. Cancers 14 (22) (2022)
Daniela Reichinger, Manuel Reithofer, Mariam Hohagen, Mirjana Drinic, Joshua Tobias, Ursula Wiedermann, Freddy Kleitz, Beatrice Jahn-Schmid, Christian F W Becker
A Biomimetic, Silaffin R5-Based Antigen Delivery Platform. Pharmaceutics 15 (1) (2022)
Daniela Reichinger, Manuel Reithofer, Mariam Hohagen, Mirjana Drinic, Joshua Tobias, Ursula Wiedermann, Freddy Kleitz, Beatrice Jahn-Schmid, Christian F W Becker
A Biomimetic, Silaffin R5-Based Antigen Delivery Platform. Pharmaceutics 15 (1) (2022)
Claire Battin, Gabriel Kaufmann, Judith Leitner, Joshua Tobias, Ursula Wiedermann, Alexander Rölle, Marten Meyer, Frank Momburg, Peter Steinberger
NKG2A-checkpoint inhibition and its blockade critically depends on peptides presented by its ligand HLA-E. Immunology 166 (4) (2022)
Daniela Reichinger, Manuel Reithofer, Mariam Hohagen, Mirjana Drinic, Joshua Tobias, Ursula Wiedermann, Freddy Kleitz, Beatrice Jahn-Schmid, Christian F W Becker
A Biomimetic, Silaffin R5-Based Antigen Delivery Platform. Pharmaceutics 15 (1) (2022)
Daniela Reichinger, Manuel Reithofer, Mariam Hohagen, Mirjana Drinic, Joshua Tobias, Ursula Wiedermann, Freddy Kleitz, Beatrice Jahn-Schmid, Christian F W Becker
A Biomimetic, Silaffin R5-Based Antigen Delivery Platform. Pharmaceutics 15 (1) (2022)
Annika De Sousa Linhares, Claire Battin, Sabrina Jutz, Judith Leitner, Christine Hafner, Joshua Tobias, Ursula Wiedermann, Michael Kundi, Gerhard J Zlabinger, Katharina Grabmeier-Pfistershammer, Peter Steinberger
Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling. Scientific reports 9 (1) (2019)

Joshua Tobias.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Joshua Tobias